BVS vs. LYRA, GUTS, CERS, TCMD, LUNG, CVRX, SGHT, SRDX, NPCE, and TLSI
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Lyra Therapeutics (LYRA), Fractyl Health (GUTS), Cerus (CERS), Tactile Systems Technology (TCMD), Pulmonx (LUNG), CVRx (CVRX), Sight Sciences (SGHT), Surmodics (SRDX), NeuroPace (NPCE), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry.
Bioventus (NYSE:BVS) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
Lyra Therapeutics has lower revenue, but higher earnings than Bioventus. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Bioventus has a net margin of -30.49% compared to Lyra Therapeutics' net margin of -4,023.11%. Bioventus' return on equity of 2.25% beat Lyra Therapeutics' return on equity.
62.9% of Bioventus shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 29.1% of Bioventus shares are owned by company insiders. Comparatively, 17.4% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bioventus presently has a consensus target price of $7.67, indicating a potential upside of 93.60%. Lyra Therapeutics has a consensus target price of $12.67, indicating a potential upside of 145.48%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Bioventus.
Bioventus received 4 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Lyra Therapeutics an outperform vote while only 59.52% of users gave Bioventus an outperform vote.
In the previous week, Lyra Therapeutics had 3 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for Lyra Therapeutics and 2 mentions for Bioventus. Lyra Therapeutics' average media sentiment score of 0.05 beat Bioventus' score of 0.00 indicating that Lyra Therapeutics is being referred to more favorably in the news media.
Bioventus has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
Summary
Lyra Therapeutics beats Bioventus on 9 of the 17 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
